Citatuzumab bogatox

Drug Profile

Citatuzumab bogatox

Alternative Names: VB6-845; VB6-845d

Latest Information Update: 21 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Viventia Biotech
  • Developer Eleven Biotherapeutics
  • Class Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action Protein synthesis inhibitors; Ribosomal protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 30 Jun 2017 Eleven Biotherapeutics plans a phase I trial in USA
  • 02 Apr 2017 Eleven Biotherapeutics announces intention to submit IND application in USA in the first quarter of 2018
  • 21 Sep 2016 Viventia Biotechnologies has been acquired by Eleven Biotherapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top